secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001193125-24-012201
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos Therapeutics names Dale Hogue as Interim CEO, effective Jan 20, 2024
----------------------------------------------------------------------------

- Dale Curtis Hogue, Jr. appointed Interim CEO; will continue serving on the Board.
- Hogue founded family office Dune Lake Capital; spent 8 years as senior analyst at Discovery Capital Management.
- Employment terms: $250,000 base salary; option to buy 600,000 shares at $0.12.
- Option vests 50,000 shares monthly over 12 months subject to continued employment; unvested shares forfeited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312524012201/0001193125-24-012201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312524012201/d732206d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-012201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer